Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Principal investigators at Nationwide Children's Hospital elected as AAAS Fellows

Brian K. Kaspar, PhD, and Veronica J. Vieland, PhD, principal investigators in The Research Institute at Nationwide Children's Hospital, have been named Fellows of the American Association for the Advancement of Science (AAAS).

26 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Manipulating PRH protein can help prevent cancer cells from unnecessary migration

Understanding how and why cancer cells move away from their original location is important to find ways to stop the spread of the disease. New findings, published in the Nature journal Oncogene, reveal how a protein, called 'PRH', is normally able to prevent cells from unnecessary migration. It is likely that this protein is less effective in cancer cells allowing the cells to venture away.

19 Nov 2013

American Thyroid Association develops ethics guidelines for thyroidology

In this changing era of health care delivery, physician guidelines on ethics are more important than ever. As each specialty area faces its own issues and dilemmas regarding patient care, scarcity of resources, and conflicts of interest, the American Thyroid Association has developed ethics guidelines specific to the field of thyroidology.

13 Nov 2013

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

The Endocrine Society today announced it has selected 15 accomplished endocrinologists as winners of the organization's prestigious 2014 Laureate Awards.

5 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

A new analysis has found that the presence of short segments of genetic material (known as microRNA) within papillary thyroid cancer tumors suggests a likelihood of recurrence after patients undergo surgery.

29 Oct 2013

Study: Gene Expression Classifier test reduces unnecessary surgeries in thyroid nodule assessment

The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment.

25 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

Ultrasound prior to thyroidectomy important for planning surgery

Ultrasound imaging is commonly used to diagnose and evaluate patients with differentiated thyroid cancer, and to determine whether the disease has spread to lymph nodes in the neck that should be removed at the time of thyroidectomy.

17 Oct 2013

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

The American Thyroid Association (ATA) recommends against the routine use of radioactive iodine after surgery to remove the thyroid in patients with low-risk papillary thyroid cancer (PTC).

17 Oct 2013

Thyroid specialists recommend thyroid function testing for pregnant women

Decreased thyroid function can have a detrimental effect on pregnancy outcomes. A majority of thyroid specialists surveyed recommend thyroid function testing for all pregnant women. The results of a survey conducted at the 2012 annual meeting of the American Thyroid Association will be delivered in a poster to be presented at the upcoming 83rd Annual Meeting of the ATA, October 16-20, 2013, in San Juan, Puerto Rico.

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

An open surgical procedure called bilateral neck exploration has been the gold standard operation for treating patients with primary hyperparathyroidism. But the development of a minimally invasive procedure to remove the parathyroid gland now offers a new option.

17 Oct 2013

Researchers find novel drug target for anaplastic thyroid carcinomas

Anaplastic thyroid carcinomas are aggressive tumors that do not respond to traditional radio- or chemotherapeutic agents, and there currently is no cure or effective treatment available. Median survival from diagnosis is 5 months, and although ATC accounts for only 1.7% of all thyroid cancers in the U.S., it is responsible for a large proportion of thyroid cancer-related deaths.

17 Oct 2013

Study shows treatment for hypothyroidism is not associated with weight loss in most people

Decreased thyroid function, or hypothyroidism, is commonly associated with weight gain. But contrary to popular belief, effective treatment with levothyroxine (LT4) to restore normal thyroid hormone levels is not associated with clinically significant weight loss in most people.

17 Oct 2013

Cdk5 protein may play crucial role in deadly form of thyroid cancer

A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression, UT Southwestern Medical Center researchers report today in Cancer Cell.

15 Oct 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Navidea receives Fast Track designation for Lymphoseek injection

Principal investigators at Nationwide Children's Hospital elected as AAAS Fellows

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Manipulating PRH protein can help prevent cancer cells from unnecessary migration

American Thyroid Association develops ethics guidelines for thyroidology

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

Study: Gene Expression Classifier test reduces unnecessary surgeries in thyroid nodule assessment

Study: Investigational drug shows promise against pancreatic cancer

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Ultrasound prior to thyroidectomy important for planning surgery

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

Thyroid specialists recommend thyroid function testing for pregnant women

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

Researchers find novel drug target for anaplastic thyroid carcinomas

Study shows treatment for hypothyroidism is not associated with weight loss in most people

Cdk5 protein may play crucial role in deadly form of thyroid cancer

Discoveries pave way for use of new therapies for advanced thyroid cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in